GlassScriptPhysician profile
George Schroeder
NPI 1265530760
$67,703.13
in general payments reported to CMS, 2019-2025
14 companies · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $20K · 2021: $21K · 2022: $6,447 · 2023: $16.46 · 2024: $112 · 2025: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $128 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.14 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65,910.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $953.03 | 2019-2021 | |
| Glaxosmithkline, LLC. | $183.42 | 2019 | |
| Pfizer INC. | $121.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.89 | 2019 | |
| Amgen INC. | $92.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $88.55 | 2024 | Farxiga |
| Novo Nordisk INC | $70.54 | 2019 | |
| Janssen Scientific Affairs, LLC | $68.08 | 2019 | |
| Insmed, INC. | $40.51 | 2024-2025 | Brinsupri, Arikayce |
| Amarin Pharma, INC. | $36.13 | 2019 | |
| Teleflex LLC | $16.46 | 2023 | Urolift |
| Ethicon US, LLC | $15.94 | 2020 | |
| Abbott Laboratories | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.